A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)

NCT05456191 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

568

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Interventions

DRUG: Asciminib
DRUG: Nilotinib

Sponsor

Novartis Pharmaceuticals